A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX

被引：1
|
作者：
Su, M-H. [1 ]
机构：
[1] NDMC Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
82P
引用
收藏
页码：S1465 / S1465
页数：1
相关论文
共 50 条
  • [1] A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
    Chen, L-T.
    Hitre, E.
    Lee, W-J.
    Bai, L-Y.
    Papai, Z.
    Kang, S. Y.
    Dvorkin, M.
    Choi, H. J.
    Oh, S. C.
    Artru, P.
    Bachet, J-B.
    ANNALS OF ONCOLOGY, 2019, 30 : 321 - 321
  • [2] EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
    Su, M.
    Chen, L.
    Hitre, E.
    Lee, W.
    Bai, L.
    Papai, Z.
    Kang, S.
    Dvorkin, M.
    Lee, M.
    Ludovic, E.
    Choi, H.
    Oh, S.
    Bodoky, G.
    Artru, P.
    Hwang, J.
    Bazin, I.
    Bosc, F.
    Bachet, J.
    Horvath, Z.
    Chang, C.
    Lin, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 23 - 23
  • [3] EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).
    Chen, Li-Tzong
    Su, Muh-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Randomized first line therapy with gemcitabine plus lipid complexed paclitaxel (ENDOTAG-1) compared with gemcitabine monotherapy in patients with locally advanced or metastatic adenocarcinoma of the pancreas A phase II study
    Lohr, M.
    Bechstein, W.
    Bodoky, G.
    Gog, C.
    Haas, S.
    Karrasch, M.
    Lilla, C.
    Lutz, M.
    Mayer, I.
    Myasoedov, D.
    Singer, M. V.
    Osynskyy, D.
    Schulze, S.
    Mescheder, A.
    Szanto, J.
    Folsch, U.
    ONKOLOGIE, 2008, 31 : 84 - 84
  • [5] A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas
    Philip, Philip A.
    Buyse, Marc E.
    Alistar, Angela T.
    Lima, Caio M. S. P. R. Rocha
    Luther, Sanjeev
    Pardee, Timothy S.
    Van Cutsem, Eric
    FUTURE ONCOLOGY, 2019, 15 (28) : 3189 - 3196
  • [6] A randomized phase III study comparing gemcitabine plus pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer.
    Richards, DA
    Kindler, HL
    Oettle, H
    Ramanathan, RK
    Van Laethem, JL
    Peeters, M
    Fuchs, M
    John, W
    Arning, M
    Von Hoff, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 315S - 315S
  • [7] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [8] Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Goldstein, David
    El Maraghi, Robert Hassan
    Hammel, Pascal
    Heinemann, Volker
    Kunzmann, Volker
    Sastre, Javier
    Scheithauer, Werner
    Siena, Salvatore
    Tabernero, Josep
    Teixeira, Luis
    Tortora, Giampaolo
    Van Laethem, Jean-Luc
    Young, Rosemary
    Wei, Xinyu
    Lu, Brian
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer
    Schwartzberg, Lee S.
    Arena, Francis P.
    Bienvenu, Bryan J.
    Kaplan, Edward H.
    Camacho, Luis H.
    Campos, Luis T.
    Waymack, J. Paul
    Tagliaferri, Mary A.
    Chen, Michael M.
    Li, Dapeng
    JOURNAL OF CANCER, 2017, 8 (10): : 1872 - 1883
  • [10] Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
    Ramanathan, R. K.
    Goldstein, D.
    Korn, R. L.
    Arena, F.
    Moore, M.
    Siena, S.
    Teixeira, L.
    Tabernero, J.
    Van Laethem, J. -L.
    Liu, H.
    McGovern, D.
    Lu, B.
    Von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 648 - 653
12345